Posts for Ticker ‘ACOR’

Top 10 Analyst Upgrades, Downgrades, Initiations (ACOR, IP, OPEN, PBR, SPWRA, ASML, LAZ, PETD, TRW, WDC)

These are this morning’s top 10 pre-market analyst upgrades, downgrades, and initiations which we have seen early from Wall Street research firms:

Acorda (NASDAQ: ACOR) Raised to Buy at Merriman Curhan Ford; Raised to Outperform at Baird.
International Paper (NYSE: IP) Started as Outperform at RBC.
OpenTable (NASDAQ: OPEN) Raised to Buy at Citigroup.
PetroBras, or Petrobras Brasileiro (NYSE: PBR) Started as Outperform at Bernstein.
Sunpower (NASDAQ: SPWRA) Raised to Outperform at Baird.
ASML (NASDAQ: ASML) Cut to Sell at Citi.
Lazard (NYSE: LAZ) Cut to Perform at Oppenheimer.
Petroleum Development (NASDAQ: PETD) Cut to Neutral at Sun Trust.
Travelers Cos (NYSE: TRV) Cut To Market Perform at KBW.
Western Digital (NYSE: WDC) Cut to Hold at Stifel Nicolaus.

You can join our open email distribution list to get updates each morning on analyst upgrades and downgrades, top day trader alerts, IPO’s and secondary offerings, Warren Buffett and other guru activity, M&A and more.

JON C. OGG
OCTOBER 15, 2009

Posted on: October 15, 2009 – 8:27 am in Analyst Calls, , , , , , , , , ,

Top Day Trader Alerts (ACOR, AVNR, INFY, SVNT, SPPI, TSM)

These are this Friday morning’s top day trader and active trader alert stocks.  We have provided a link through to VSInvestor.com with more detailed price and volume analysis on each stock below:

Acorda Therapeutics, Inc. (NASDAQ: ACOR) down on FDA link that made its data public.

AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) is the top gainer so far as Zenvia data showed positive results at higher doses.

Infosys Technologies Limited (NASDAQ: INFY) beat earnings, but shares are down about 3%.

Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) is trading up over 4% after a secondary offering, and an upgrade probably helped here.

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) is down sharply on complete response letter from FDA for FUSILEV in advanced metastatic colorectal cancer going against it.

Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE: TSM) is up marginally on over 1 million shares a sales drop still met plan.

You can join our open email distribution list to get updates each morning on analyst upgrades and downgrades, top day trader alerts, IPO’s and secondary offerings, Warren Buffett and other guru activity, M&A and more.

JON C. OGG
October 9, 2009

Posted on: October 9, 2009 – 8:57 am in After-Hours Activity, Pre-Market Activity, Trading Alert, , , , , ,

Top Analyst Upgrades (ACOR, CCE, CREE, CVS, ICE, SVVS)

These are the top pre-market analyst upgrades and positive research calls we have seen from Wall Street early this Wednesday morning:

Acorda Therapeutics (ACOR) Raised to Overweight at Piper Jaffray.
Coca-Cola Entertainment (CCE) Raised to Buy at Argus.
Cree (CREE) Raised to Buy at Merriman Curhan Ford.
CVS Caremark (CVS) Raised to Outperform at William Blair.
IntercontinentalExchange (ICE) Raised to Market Perform at KBW.
Savvis (SVVS) Raised to Overweight at Morgan Stanley.

JON C. OGG
AUGUST 5, 2009

Posted on: August 5, 2009 – 7:57 am in Analyst Calls, , , , , ,

MS Setback for Acorda (ACOR, BIIB)

burning-money-pic42Acorda Therapeutics, Inc. (NASDAQ: ACOR) is taking it right on the chin this morning.  The company announced that it has received a “refuse to file letter” from the FDA regarding its New Drug Application for Fampridine-SR.  Unfortunately, this is supposed to be for a novel therapy being developed to improve walking ability in people with multiple sclerosis.
Read More »

Posted on: March 31, 2009 – 8:54 am in Biotech, FDA, Trading Alert, ,

Early Bird Analyst Upgrades (ACOR, BIIB, BKC, CHRT, OSG, SLB, TSO, WMT)

These are some of the top pre-market upgrades from analysts which we have seen in the early hours this Monday morning:

  • Acorda Therapeutics (ACOR) Raised to Outperform at Baird.
  • Biogen Idec (BIIB) Raised to Outperform at Baird and Raised to Buy at Deutsche Bank.
  • Burger King (BKC) Raised to Outperform at Wachovia.
  • Chartered Semiconductor (CHRT) Raised to Neutral from Sell at Goldman Sachs.
  • Overseas Shipholding (OSG) Raised to Outperform at Oppenheimer.
  • Schlumberger (SLB) Raised to Buy at Goldman Sachs.
  • Tesoro (TSO) Raised to Neutral at JPMorgan.
  • Wal-Mart Stores (WMT) Raised to Overweight at JPMorgan.

Jon C. Ogg
November 3, 2008

Posted on: November 3, 2008 – 7:38 am in Analyst Calls, , , , , , , ,

The Week’s Top Biotech Movers For Next Week (TRCA, ACOR, ISPH, ONCY, PCYC, SQNM, IDEV, LGND, AUXL)

Out of the daily movers this last week, many of the top winners and losers were from news in many of the smaller biotech stocks.  We prepared a list of the winners and sinners from our daily review at BioHealthInvestor.com and gave a summary regarding the moves on each.  It is becoming more obvious that many small and mid-sized biotechs are going to be gobbled up by European or Asian biotech and pharma companies seeking the dollar-discount right now.

For starters, we ran a summary of the key moving pieces out of the American Society of Clinical Oncology (ASCO).  No review would be complete without it. Stocks covered: (AVAN, PFE, CELG, IMCL, DNA)

ACQUISITION NEWS
Tercica, Inc. (NASDAQ: TRCA) bites the dust as its own company the latest small cap biotech received a huge premium acquisition from a foreign buyer, with a 104% premium.  FULL DETAILS

MAJOR WINNERS
Acorda Therapeutics Inc. (NASDAQ: ACOR) had a great week after it announced positive data from a second Phase III study of its Fampridine-SR for patients’ walking abilities in MS patients.  FULL DETAILS

Inspire Pharmaceuticals Inc. (NASDAQ: ISPH) surged after reaching its primary endpoint in Phase III trial of Denufosol for Cystic Fibrosis.  FULL DETAILS

Oncolytics Biotech Inc. (NASDAQ: ONCY) gained after the Canadian biotech’s positive Phase II studies of intravenous REOLYSIN® in patients with sarcomas metastatic to the lung.  FULL DETAILS

Pharmacyclics Inc. (NASDAQ: PCYC) gained after its Phase 1/2 trial of motexafin gadolinium plus antibody targeted radiation therapy showed a high complete response rate in patients with non-Hodgkin’s lymphoma.  FULL DETAILS

Sequenom Inc. (NASDAQ: SQNM) surged after it announced its progress with a non-invasive technology that detects Down syndrome. FULL DETAILS

MAJOR LOSERS
Indevus Pharmaceuticals Inc. (NASDAQ: IDEV) tanked after an FDA request should cause a two-year delay in approving NEBIDO.  FULL DETAILS

MIXED REVIEW
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is one we gave a full pro and con review covering the upside of the stock and the negative side of the stock.  FULL DETAILS

Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL) was a strange stock this week.  The company reported great news but shares slid before the market figured out it had misinterpreted news in the company.  INITIAL DETAILS

Jon C. Ogg
June 7, 2008

Posted on: June 7, 2008 – 6:01 am in Biotech, The Week, , , , , , , , ,

Biotech Busine$$ Daily (ACOR, CERS, DNDN, STEM, TCM)

Biotechs always have some news movers regardless of which direction the markets are headed.  Here are some of the top movers in biotech today, although we would note that many of the largest market cap biotech stocks are up on a day that the DJIA, S&P 500, and NASDAQ are dragging lower.

Acorda Therapeutics (NASDAQ: ACOR) down 5% today to $19.56. Yesterday, a study the company sponsored on multiple sclerosis was released showing the negative impact MS had on people suffering from the disease. The 52 week range is $15.80 to $28.14.

Cerus Corp. (NASDAQ: CERS) stock up over 6% today to $543 on an announcement that the 32 studies of their INTERCEPT Blood System, a system that assists patients that underwent blood transfusions and avian flu deactivation, will be presented at the International Congress of the International Society of Blood Transfusion. The 52-week range is $4.18 to $10.29

Dendreon (NASDAQ: DNDN) up almost 8% in mid-day trading on no new news. Stocks are trading $0.40 higher at $5.16. The stock seems to be recovering from a slide March 12 when the company changed its tactics on for Phase III testing on prostate cancer immunotherapy Provenge.

StemCells Inc. (STEM) up by almost 8% today to $1.49, possibly in response to Nancy Reagan’s endorsement of Republican presidential nominee, John McCain, both supporters of stem cell research. The 52-week range is $1.00 to $3.09.

Tongjitang Chinese Medicines Co. (NASDAQ: TCM) up today on news that the company has appointed Morgan Stanley Asia Limited as its financial advisor. Shares have edged up $0.45 or by 5%, to $8.51 in mid-day trading on relatively high trading volume. The 52 week high is $12.88.

Rachel Lopez
March 26, 2008

Posted on: March 26, 2008 – 1:18 pm in Biotech, , , , ,

The Day In Biotech Stocks (January 28, 2008) (ACOR, BIIB, CELG, PHRM, CRXX, LIPD, MDVN, PCOP)

Acorda Therapeutics inc. (NASDAQ: ACOR) showed late stage trial results on its drug candidate Fampridine-SR for treating multiple sclerosis.  This data showed that Fampridine, which is designed to treat multiple sclerosis, did not increase patients’ QT interval Associated with Arrhythmia more than a placebo did.  Shares were up $4.29 at $26.07 mid-day.

Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is set to report earnings after the closing bell, with First Call estimates at -$0.44 EPS on revenues of $202.58 million Shares were up less than 1% at $32.74 on the day ahead of earnings.

Carl Icahn has nominated three individuals for the board of directors in Biogen-Idec (NASDAQ: BIIB) in his activist efforts to move the shares.  Biogen-Idec shares were down $0.90 to $58.02 mid-day.

Celgene Corporation (NASDAQ: CELG) was cleared today by German regulation to proceed with its acquisition of Pharmion. Stocks are up over 3% to $53.31 at mid-day. Pharmion Corp. (NASDAQ: PHRM) shares were up 1.8% to $67.44.

CombinatoRx Inc. (NASDAQ: CRXX) shares fell almost 7% to $4.80 mid-day on thin trading volume.  Technically there was no news today, although this followed guidance last week of losses below view.

Lipid Sciences, Inc. (NASDAQ: LIPD) announced positive trial results in non-human SIV-infected primates in its proprietary deplidated autogolous virus vaccine. Share prices were up more than 15% or $0.09 to $0.65 at mid-day.

Medivation, Inc. (NASDAQ: MDVN) rose after it announced that, based on its end-of-Phase 2 meeting with the FDA, it plans to begin a pivotal confirmatory Phase III trial of Dimebon for mild-to-moderate Alzheimer’s Disease in the second quarter of 2008.  Shares rose $2.36 to $17.21 by mid-day on this data.

Pharmacopeia, Inc. (NASDAQ: PCOP) shares fell over 10% to $4.37 at mid-day on thin-trading volume. There has been no recent news.

Jon C. Ogg
January 28, 2008

Posted on: January 28, 2008 – 1:43 pm in Biotech, , , , , , , , , , ,

Pre-Market Stock News (July 20, 2007)

(ACOR) Acorda COO resigned to pursue other interests.
(AMD) Advanced Micro Devices traded up 4% after revenues were ahead of plan on processor sales.
(AUY) Yamana Gold makes business combination offer for Meridian Gold.
(BVF) Biovail received a non-approval letter from the U.S. FDA for its NDA for BVF-033.
(C) Citigroup $1.24 EPS vs $1.13 estimate, Revenues $25.6 Billion vs. $24.88B est.
(CAT) Caterpillar $1.24 EPS vs $1.49 estimate.
(ERIC) Ericsson ADR’s trading down over 4% after earnings rose 12% overseas.
(MSFT) Microsoft traded down almost 1% after meeting expectations.
(OWW) Orbitz IPO priced 34 million shares at $15.00.
(GOOG) Google traded down 7% after missing EPS on higher expenses.
(PRSP) Prosperity Bancshares $0.52 EPS vs $0.52 estimate.
(RHHBY) Roche profit rose 24% overseas; named new chief for diagnostics unit.
(SLB) Schlumberger $1.02 EPS vs $0.95 estimate.
(SNDK) SanDisk trading up over 4% after beating earnings.
(SNTS) Santarus announces achievement of $5 million milestone payment under license agreement wit Schering-Plough.
(SON) Sonoco $0.56 EPS vs $0.59 estimate.
(WB) Wachovia $1.23 EPS vs $1.22 estimate.
(WHR) Whirlpool $2.00 EPS vs $1.83 estimate.

Jon C. Ogg
July 20, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: July 20, 2007 – 7:21 am in Pre-Market Activity, , , , , , , , , , , , , , , , , , ,

Earlybird Analyst Calls (June 19, 2007)

ACLI cut to Hold at Deutsche Bank.
ACOR raised to Buy at B of A.
AGO cut to Underweight at JPMorgan.
ANAD started as Buy at Oppenheimer.
ANET cut to Neutral at Baird.
ATHR started as Buy at Oppenheimer.
AV cut to Mkt Perform at JMP Securities.
BAC raised to Buy at UBS.
BEAS cut to Neutral at UBS.
CHD started as Buy at Sun Trust Robinson Humphrey.
CI raised to Neutral at B of A.
EGLE started as Neutral at JPMorgan.
EPIC started as Buy at Sun Trust Robinson Humphrey.
GNK started as Overweight at JPMorgan.
GNTX raised to Buy at B of A.
KNX raised to Outperform at Wachovia.
LCC raised to Neutral at UBS.
MCHP cut to Mkt Perform at Piper Jaffray.
QMAR started as Neutral at JPMorgan.
SDXC started as Buy at Kaufman Bros.
SKH started as Buy at Jefferies.
SRE raised to Buy at Citigroup.
TZIX started as Buy at Deutsche Bank.
WERN raised to Outperform at Wachovia.
YRCW cut to Mkt Perform at Wachovia.

Jon C. Ogg
June 19, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: June 19, 2007 – 6:20 am in Analyst Calls, , , , , , , , , , , , , , , , , , , , , , , , ,

Pre-Market Stock News (June 6, 2007)

(AAUK) Anglo American’s CEO will become a non-executive member of the board of directors at BP (BP).
(ACAD) Acadia Pharmaceuticals traded up over 10% after Jim Cramer touted the stock as a speculative play for trading the upcoming data on its schizophrenia and Parkinson’s treatment.
(ACOR) Acorda Therapeutics Starts Second Phase 3 Trial of Fampridine-SR in MS
(AMTD) TD AMERITRADE was notified that JANA and S.A.C. funds have secured an interest of roughly 8.6% stake to pressure the companies to enter a merger.
(AZN) AstraZeneca CFO leaves to join Goldman Sachs.
(CROX) Crocs is launching a fashionable line of high heel and flats for women to appeal to fashion conscious women.
(CSC) Computer Sciences Corp. may look to acquire iSoft Group plc in the UK.
(ETFC) E*Trade trading up 3% on AMERITRADE news.
(FCS) Fairchild Semiconductor reaffirmed Q2 growth targets.
(GSK) GlaxoSmithkline defends Avandia saying it does not increase heart risks.
(KFY) Korn Ferry $0.37 adjusted EPS versus $0.34 estimates.
(MAIR) MAIR Holdings -$0.06 EPS vs -$0.05e.
(PNRA) Panera trading down $7.00 on an earnings warning of $0.38-0.40 vs $0.47-0.51e.
(PLUG) Plug Power named new CFO.
(PRU) Prudential lays off 420 in a research phase out, will cease covering all equities immediately.
(RUS) Russ Berrie rejected an $18.00 buyout as an undervalued deal.
(SCHW) Charles Schwab traded up 1% after the AMERITRADE news.
(SIRI) Sirius Satellite Radio announced a $250 million term-loan from Morgan Stanley.
(STAR) Starent priced a 10.5 million share IPO at$12.00, above the $9.00 to $11.00 range.
(WFMI) Whole Foods is facing a deal blockage by the FTC over a ‘natural foods market disruption’ according to FTC.

Jon C. Ogg
June 6, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: June 6, 2007 – 7:13 am in Pre-Market Activity, , , , , , , , , , , , , , , , , , , ,